Immuneel Therapeutics Raises $10.5 million in Series B Round

The funding round included investments from Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals. Existing investors such as Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also participated.

Immuneel plans to use the fresh funding to expand its manufacturing capacity, advance the development of its cell and gene therapy treatments, and grow its presence in markets across the Asia-Pacific and Middle East regions.

Immuneel Therapeutics Founder Kiran Mazumdar-Shaw said, “This company was founded with the belief that advanced cell therapies should not remain confined to a small segment of patients or a handful of geographies. This fundraise strengthens our ability to build a globally competitive CAR-T platform from India combining deep science, scalable manufacturing and significantly improved affordability. We believe India can play a meaningful role in shaping the future of cell and gene therapy for the world."

Immuneel Therapeutics CEO Amit Mookim said "Qartemi’s commercialisation proved we can deliver world class CAR-T outcomes at a fraction of Western costs. This Series B financing accelerates what comes next: a bold international expansion and a next-generation pipeline that will redefine how cell therapies reach patients globally. We are not just building a company—we are building a new global standard of care from India."

Founded in 2018 by Kiran Mazumdar-Shaw, Siddhartha Mukherjee, and Kush Parwar, Bengaluru-based Immuneel is a biotechnology company that develops advanced cell and gene therapies for cancer treatment.

Since its founding, the company has raised more than $40 million in funding, including a $15 million Series A round in 2022 from investors such as Eight Roads Ventures, True North, and F-Prime Capital.

Immuneel recently launched Qartemi, which it describes as India's first approved CAR-T cell therapy for patients with Non-Hodgkin Lymphoma and leukemia. The company is also working with partners in Australia and Southeast Asia to expand access to advanced cancer treatments in more countries.

Read Also- VinDynamics and Skild AI Partner to Accelerate Humanoid Robotics Development